Patient Characteristics and Treatment Patterns from Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis from Select Sickle Cell Centers

Grant

Awarded By

Total Award Amount

  • 197740.00

    • Direct Costs

  • 178144.00

    • Sponsor Award Id

    • Contributor

  • Gerhard Hellemann   Investigator  
  • Jeanine Dumas   Investigator  
  • Jeffrey Lebensburger   Investigator  
  • Julie Kanter   Principal Investigator